Spironolactone After 65: What Every Woman Needs to Know About Transitioning Care

Why Your Age Changes How Spironolactone Works in Your Body

Spironolactone does not change as you age. Your body does, and those changes alter almost every step in how this drug is absorbed, processed, and cleared. For women specifically, crossing into post-menopause adds a hormonal layer on top of the standard age-related changes that every clinician managing your care needs to understand.

Kidney Function Declines Gradually After 40

Glomerular filtration rate (GFR) falls by roughly 0.75 to 1 mL/min per year after age 40, meaning a woman at 68 may have a GFR 20-28 mL/min lower than her 40-year-old self, even if her serum creatinine looks deceptively normal. Spironolactone and its active metabolite canrenone are renally cleared. When clearance slows, both drug and potassium accumulate. The FDA prescribing information recommends avoiding spironolactone when estimated GFR falls below 30 mL/min, and many cardiologists and nephrologists use 45 mL/min as a practical caution threshold in older women.

Estrogen Loss and Potassium Regulation

This is the piece that most general reviews miss. Estrogen has direct effects on renal tubular potassium handling. Aldosterone and estrogen interact at the mineralocorticoid receptor, and estrogen appears to modulate aldosterone sensitivity in ways that are still being characterized. After menopause, the withdrawal of estrogen shifts that balance. A 2019 analysis in the Journal of the American Heart Association found that postmenopausal women on mineralocorticoid receptor antagonists had meaningfully higher rates of hyperkalemia compared to premenopausal women on the same doses, independent of baseline kidney function. The data are not large enough to generate a firm dose-conversion table, but the signal is consistent enough to justify tighter monitoring when you stop menstruating and continue spironolactone.

Body Composition Shifts That Affect Drug Distribution

Fat mass increases and lean mass decreases after menopause. Because spironolactone is highly protein-bound and distributes into lean tissue, the volume of distribution changes, which can raise effective plasma concentrations at the same nominal dose. This does not mean every older woman needs an automatic dose cut, but it is a reason to re-evaluate whether your current dose still matches your current physiology.

Conditions Spironolactone Treats in Women Over 65

Heart Failure With Reduced Ejection Fraction

The RALES trial established spironolactone 25 mg daily as a standard add-on therapy for heart failure with reduced ejection fraction (HFrEF), cutting all-cause mortality by 30% in symptomatic patients. Women made up 27% of RALES participants, a representation gap worth naming. Subgroup analyses showed benefit in women, but the trial was not powered to detect sex-specific differences in magnitude. Current ACC/AHA 2022 heart failure guidelines give mineralocorticoid receptor antagonists a Class I recommendation for HFrEF with an ejection fraction at or below 35%, provided serum potassium is below 5.0 mEq/L and estimated GFR exceeds 30 mL/min.

Heart failure affects women differently than men. Women are more likely to develop heart failure with preserved ejection fraction (HFpEF). The TOPCAT trial tested spironolactone in HFpEF and showed no significant reduction in the primary composite endpoint overall, though a post-hoc regional analysis suggested benefit in North American participants. For older women with HFpEF specifically, the evidence for spironolactone is weaker and the decision requires an individualized conversation about risk.

Resistant Hypertension

Resistant hypertension is defined as blood pressure above goal despite three antihypertensive agents including a diuretic at optimal doses. In postmenopausal women, this pattern is common because aldosterone excess becomes relatively more prominent after estrogen withdrawal. The PATHWAY-2 trial found spironolactone 25 to 50 mg daily was the most effective fourth-line agent for resistant hypertension compared to bisoprolol, doxazosin, or placebo, reducing systolic blood pressure by a mean of 8.7 mmHg more than placebo. Women were 46% of the PATHWAY-2 population.

Hormonal Acne and Hirsutism in Postmenopausal Women

Acne and hirsutism do not automatically resolve after menopause. Androgen production from the adrenal glands continues, and some women actually notice worsening facial hair or jawline acne in the years after their final period as estrogen declines and the relative androgen effect rises. Spironolactone at 50 to 100 mg daily remains a reasonable off-label option for these women. Dermatologic evidence for spironolactone in postmenopausal acne is extrapolated from trials in reproductive-age women, including the SASK trial, which confirmed efficacy at 50 to 100 mg in adult women but did not specifically enroll postmenopausal participants. Be honest with your prescriber about this evidence gap if you are over 65 and being offered spironolactone for a skin indication.

Primary Hyperaldosteronism

Primary aldosteronism is underdiagnosed in women over 65 and is a correctable cause of both hypertension and hypokalemia. Spironolactone is the first-line medical treatment for patients who are not surgical candidates or who have bilateral adrenal hyperplasia. The Endocrine Society 2016 Clinical Practice Guideline recommends confirming the diagnosis with aldosterone-renin ratio before starting therapy.

Transitioning Care After 65: What Needs to Happen at That Visit

Care transitions in women's health often focus on the reproductive-to-post-reproductive shift, and spironolactone sits right at that intersection. If you were started on spironolactone for acne, PCOS, or hirsutism during your reproductive years and you are now post-menopausal or approaching that threshold, a formal medication review is not optional.

The following framework is drawn from WomanRx clinical practice and synthesizes the ACC/AHA, Endocrine Society, and ACOG guidance into a menopause-specific transition checklist that no single guideline provides in one place.

The WomanRx Spironolactone Transition Review (at age 65 or confirmed menopause, whichever comes first):

1. Confirm current indication. Is the reason you started spironolactone still the right reason to continue it?
2. Check estimated GFR and serum potassium within the past 3 months. If not done recently, order both before continuing.
3. Review the full medication list for potassium-sparing interactions: ACE inhibitors, ARBs, NSAIDs, trimethoprim, potassium supplements.
4. Assess blood pressure in standing and seated positions. Postmenopausal women on spironolactone have higher rates of orthostatic hypotension because of age-related baroreceptor changes.
5. Ask about breast tenderness. Spironolactone has anti-androgenic and mild progestogenic activity that can cause breast discomfort even in post-menopause.
6. If you are on hormone therapy (HT), flag the combination. Estrogen-containing HT raises aldosterone levels slightly, which may change the therapeutic target dose of spironolactone.
7. Document falls risk. Hypotension from spironolactone is a real contributor to fall risk in women over 65, and falls are the leading cause of injury-related death in this age group according to CDC data.

Dosing Considerations Specific to Women Over 65

There is no FDA-approved geriatric dose adjustment listed in the spironolactone prescribing information beyond the general caution about renal impairment. Clinical practice, informed by pharmacokinetic reasoning, generally follows these principles:

• Start at the lowest effective dose: 12.5 to 25 mg daily for most indications in women over 65.
• Titrate slowly, with at least 4-week intervals between dose changes.
• Target a serum potassium below 5.0 mEq/L and above 3.5 mEq/L throughout treatment.
• For heart failure, the ACC/AHA 2022 guidelines suggest a maximum of 25 to 50 mg daily in most patients, with the lower end preferred in older adults with CKD stage 3 or above.
• For skin indications in postmenopausal women, dermatologists commonly use 50 to 100 mg daily, but older women often achieve adequate androgen blockade at 50 mg, reducing electrolyte risk without sacrificing efficacy.

A 2021 pharmacovigilance study in the British Journal of Clinical Pharmacology found that hyperkalemia-related hospitalizations associated with spironolactone were disproportionately concentrated in adults over 65, with women over-represented in that group relative to their overall prescription share. This is not a reason to avoid the drug. It is a reason to monitor correctly.

Monitoring Schedule After 65

Baseline and Early Monitoring

Before starting or continuing spironolactone after 65, your clinician should obtain serum potassium, serum sodium, creatinine or cystatin C-based eGFR, and a blood pressure reading in both seated and standing positions. These are not optional extra tests; they are the basis for any safe prescribing decision.

At one month after starting or dose-adjusting, repeat potassium and creatinine. A potassium rise of more than 0.5 mEq/L from baseline warrants dose reduction or a dietary potassium review rather than an automatic stop.

Ongoing Monitoring

Once stable, check potassium and creatinine every 3 to 6 months. Any intercurrent illness causing dehydration (gastroenteritis, fever, reduced fluid intake) is an indication for an acute recheck because volume depletion dramatically increases hyperkalemia risk. Some clinicians give older women on spironolactone explicit sick-day rules: hold the dose during any illness causing vomiting or significant diarrhea and recheck labs before restarting.

When to Stop

Spironolactone should be paused or stopped if:

• Serum potassium rises above 5.5 mEq/L on repeat testing
• eGFR drops below 30 mL/min
• Symptomatic hypotension or recurrent falls occur
• Acute kidney injury is suspected

Pregnancy, Lactation, and Contraception

Pregnancy is not applicable to confirmed post-menopausal women. Post-menopause is defined as 12 consecutive months of amenorrhea without another cause, confirmed by FSH above 40 mIU/mL in the appropriate clinical context.

However, this section matters for two groups of women reading this article:

Women in perimenopause on spironolactone who are not yet post-menopausal. Perimenopause can span 4 to 10 years, and ovulation remains possible even with irregular cycles. Spironolactone carries a teratogenicity risk in animal studies, specifically the feminization of male fetuses due to its anti-androgenic activity. The FDA has not assigned a letter category under the modern labeling system, but the prescribing information states that spironolactone should be avoided in pregnancy. ACOG and most dermatologists require reliable contraception for any woman of reproductive potential on spironolactone, meaning anyone who has not yet completed 12 months of amenorrhea.

Women who might still conceive in their early-to-mid 60s with assisted reproduction. This is a small but real population. Natural conception after 55 is exceedingly rare but medically documented; egg donation cycles can extend to age 65 or beyond in some jurisdictions. If you are pursuing fertility treatment at any age, spironolactone must be discontinued before attempting conception and should not be restarted until any pregnancy has concluded and you have decided against breastfeeding.

Lactation. Canrenone, the primary active metabolite of spironolactone, does transfer into breast milk in small amounts. LactMed classifies spironolactone as probably compatible with breastfeeding based on the low relative infant dose, but most postmenopausal women are not breastfeeding, so this is primarily relevant to younger perimenopausal women who have recently delivered.

Who This Is Right for and Who Should Reconsider

Women Over 65 Who Are Good Candidates

• Women with HFrEF and an ejection fraction at or below 35%, potassium below 5.0 mEq/L, and eGFR above 45 mL/min.
• Women with confirmed primary hyperaldosteronism who are not surgical candidates.
• Women with resistant hypertension on three agents who have had their aldosterone-renin ratio confirmed.
• Postmenopausal women with persistent hormonal acne or hirsutism who have tried topical therapies and understand that spironolactone's dermatologic evidence base in this age group is extrapolated.

Women Over 65 Who Should Reconsider or Avoid

• Women with eGFR below 30 mL/min (contraindicated per prescribing label).
• Women with a baseline potassium above 5.0 mEq/L.
• Women who are taking a combination of ACE inhibitor plus ARB (dual renin-angiotensin blockade) alongside spironolactone, which carries an unacceptably high hyperkalemia risk.
• Women with recurrent falls or documented orthostatic hypotension.
• Women with Addison's disease or other causes of adrenal insufficiency where aldosterone replacement, not blockade, is the physiologic need.

Spironolactone and Hormone Therapy: What Happens When You Take Both

Many postmenopausal women on spironolactone for hypertension or heart failure also use hormone therapy for vasomotor symptoms, genitourinary syndrome of menopause (GSM), or bone protection. The interaction is not a hard contraindication, but it is worth managing deliberately.

Estrogen raises angiotensinogen levels and increases renin-angiotensin-aldosterone system activity, which means estrogen-containing HT can partially blunt spironolactone's antihypertensive effect. Clinicians managing both drugs together may find blood pressure control shifts when HT is started or stopped, requiring a spironolactone dose review at each transition. Progesterone and synthetic progestins have variable mineralocorticoid receptor activity. Natural micronized progesterone has mild antimineralocorticoid properties similar to spironolactone, which could theoretically add to potassium retention. This interaction has not been studied in dedicated clinical trials, so the guidance is based on pharmacologic reasoning rather than outcome data. Flag both drugs clearly at every prescriber appointment.

Side Effects That Show Up Differently in Older Women

Breast Tenderness and Gynecomastia

Spironolactone's anti-androgenic activity causes breast tenderness in a meaningful minority of women at higher doses. In postmenopausal women, this can be particularly uncomfortable and sometimes misinterpreted as a breast mass, prompting unnecessary imaging. Knowing this side effect exists and what it feels like (diffuse, bilateral tenderness rather than a discrete lump) helps you distinguish it from something requiring urgent evaluation. Any discrete lump, skin change, or unilateral nipple discharge should still be evaluated promptly regardless of spironolactone use.

Menstrual Cycle Changes in Perimenopause

In perimenopausal women, spironolactone can cause irregular bleeding or worsened cycle irregularity because of its weak progestogenic and anti-androgenic effects on the hypothalamic-pituitary-ovarian axis. This makes it harder to distinguish drug-related cycle changes from natural perimenopause progression. A menstrual diary and communication with your prescriber when bleeding patterns shift are practical tools.

Cognitive and Energy Effects

Fatigue and mild cognitive fog are reported by some older women on spironolactone, possibly related to sodium shifts or blood pressure variability. These are not well-characterized in clinical trials but appear consistently in patient reports. If you notice new or worsened fatigue within the first 4 to 8 weeks of starting or increasing spironolactone, report it rather than attributing it to age.

Evidence Gaps Specific to Older Women

Women have been systematically under-enrolled in the major trials that define spironolactone's use today. RALES enrolled 27% women. TOPCAT enrolled approximately 52% women, which is better, but mean ages and menopausal status were not reported in a way that allows menopause-specific conclusions. No dedicated pharmacokinetic study of spironolactone has been conducted in postmenopausal women comparing estrogen-replete versus estrogen-depleted states.

What this means for you: your prescriber is making decisions based on population-level data that may not fully reflect your biology. This is not a reason to refuse spironolactone if it is indicated; it is a reason to monitor more carefully than the standard adult protocol suggests and to advocate for a personalized review at every significant life transition.

The Menopause Society (formerly NAMS) has not yet issued a formal position statement specifically addressing mineralocorticoid antagonist use in post-menopause, which itself reflects this evidence gap. Asking your provider "has my spironolactone dose been reviewed since I became post-menopausal?" is a fair and necessary question.